GENFIT CORP.
245 First Street - 18th Floor
Suite 1806
Cambridge
Massachusetts
02142
United States
Tel: 617-444-8416
Fax: 617- 444-8405
Website: http://www.genfit.com/
Email: Karen.Miller@Genfit.com
About GENFIT CORP.
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
175 articles with GENFIT CORP.
-
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018
2/4/2019
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
-
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
-
GENFIT announces its Financial Calendar for 2019
1/21/2019
GENFIT today announces its provisional financial calendar for 2019
-
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)
1/3/2019
Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
12/17/2018
Data Safety Monitoring Board (DSMB) recommended the continuation of RESOLVE-IT without any modifications, based on the pre-planned review of safety data, including adverse events and laboratory data
-
GENFIT: Positive Phase 2 Results from Study of Elafibranor in Primary Biliary Cholangitis
12/6/2018
Elafibranor successfully meets primary endpoint with high statistical significance of p<0.001
-
GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis
12/3/2018
- Phase 2 study targeting a patient population with NASH-induced Stage 2 or 3 fibrosis - Anti-fibrotic effect of nitazoxanide to be evaluated by several approaches including an innovative method to quantify hepatic fibrogenesis flux rates
-
GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis
12/3/2018
Phase 2 study targeting a patient population with NASH-induced Stage 2 or 3 fibrosis
-
GENFIT ANNOUNCES PLANS TO CONDUCT REGISTERED PUBLIC OFFERING IN THE UNITED STATES
11/19/2018
GENFIT SA today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares (“ADSs”), in the United States and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission
-
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NAS...
-
GENFIT: Third quarter 2018 financial information (Unaudited financial information under IFRS)
10/24/2018
Cash and cash equivalents of €219.9 million at September 30, 2018
-
GENFIT: New data to be presented at 2018 AASLD meeting, ahead of key results expected in 2018 and 2019
10/2/2018
KOL event to be held ahead of expected data release with elafibranor in PBC by end of 2018 (Phase 2) and in NASH end of 2019 (Phase 3)
-
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
-
GENFIT: Further Details on Management Changes
9/26/2018
GENFIT today provides further details on the management changes announced in its September 24, 2018 press release.
-
GENFIT: Gearing Up for 2019 with Organizational Changes
9/24/2018
GENFIT today announces some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical company.
-
2018 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €238M AND SIGNIFICANT ADVANCES IN THE CLINICAL DEVELOPMENT OF ELAFIBRANOR
9/24/2018
Completion of enrollment of approx. 1000-patient study cohort for Phase 3 RESOLVE-IT study, on the basis of which conditional marketing approval for elafibranor in NASH could be obtained in 2020. Interim data readout expected by end of 2019.
-
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
-
GENFIT announces its upcoming participation in a number of investor and NASH-specific events over the next two months
9/7/2018
GENFIT today announces its participation in numerous investor healthcare conferences both in Europe and the United States.
-
GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC
8/28/2018
GENFIT (Euronext: GNFT - ISIN: FR0004163111), is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases today announces the completion of enrolment in the Phase 2a trial evaluating elafibranor in PBC (Primary Biliary Cholangitis), a rare liver disease.